摘要
背景与目的吉非替尼是选择性表皮生长因子受体酪氨酸激酶抑制剂,用于治疗非小细胞肺癌,特别是腺癌。本研究的目的是探讨吉非替尼在晚期肺腺癌中的疗效、副反应及影响因素。方法收集26例晚期肺腺癌,应用吉非替尼250mg口服,每日1次,直至出现任何疾病进展的客观证据或发生不可耐受的不良事件。定期复查,并进行生存分析。结果26例患者中CR1例(3.8%),PR11例(42.3%),SD9例(34.6%),PD5例(19.2%)。客观缓解率为46.2%,疾病控制率为80.8%。其中位无进展生存期为8.2个月,中位总体生存期为10.4个月,1年生存率为31.6%。年龄(<70岁)、产生皮疹及CEA降低与较好的预后有密切关系,吉非替尼治疗级别及化疗次数等因素与预后无明显关系。用药前平均PS(ECOG)为3.0,用药后平均为1.8。平均症状缓解时间为5.2天。结论吉非替尼是一种疗效好、副作用少、可以明显提高肺腺癌患者生活质量的靶向治疗药物,对没有化疗条件的腺癌患者,可以作为一线治疗首选用药。
Background and objective Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor which is used to treat advanced non-small cell lung cancer, especially adenocarcinoma. The aim of this study is to evaluate the efficacy, side effects and prognostic factors of gefitinib in adenocarcinoma of the lung. Methods A total of 26 patients with advanced adenocarcinoma of the lung were enrolled in the study. Gefitinib was orally administered 250mg once daily until disease progression or the occurrence of intolerable toxicity. They were evaluated regularly and their survival was analyzed. Results In 26 patients, there was 1 with complete regression (3.8%), 11 with partial response (42.3%), 9 with stable disease (34.6%) and 5 with progression of disease (19.2%). The objective response rate was 46.2% and the disease control rate was 80.8%. The median progression-free survival time was 8.2 months and the median overall survival time was 10.4 months. The 1-year survival rate was 31.6%. Age (<70 years old), skin rash and CEA decrease were significantly related to longer survival, however, times of prior chemotherapy and gefitinib treatment stage did not influence the survival. Mean PS (ECOG) was 3.0 before treatment, and 1.8 after treatment. Mean symptom relief time was 5.2 days. Conclusion Gefitinib is an effective target drug with slight side effect. It can significantly improve quality of life of patients with adenocarcinoma. It can be used as first-line therapy to patients who are not suitable for chemotherapy.
出处
《中国肺癌杂志》
CAS
2007年第3期229-233,共5页
Chinese Journal of Lung Cancer
关键词
肺肿瘤/腺癌
吉非替尼
靶向治疗
Lung neoplasms/adenocarcinoma Gefitinib Target therapy
